antihemophilic factor

(redirected from Kogenate)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Kogenate: Xyntha

an·ti·he·mo·phil·ic factor

 (ăn′tē-hē′mə-fĭl′ĭk, ăn′tī-)
n. Abbr. AHF
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.antihemophilic factor - a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia Aantihemophilic factor - a coagulation factor (trade name Hemofil) whose absence is associated with hemophilia A
clotting factor, coagulation factor - any of the factors in the blood whose actions are essential for blood coagulation
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
M2 EQUITYBITES-May 12, 2014-Bayer receives approval from US FDA for Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis in adults with hemophilia A
M2 PHARMA-May 12, 2014-Bayer receives approval from US FDA for Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis in adults with hemophilia A
Sur le plan medical, le Kogenate qui a, depuis son introduction en Algerie, a ameliore, significativement, le traitement des hemophiles, fetera ses 25 annees d'existence cette annee.
(2009) Evolution of recombinant factor VIII safety: KOGENATE and Kogenate FS/Bayer.
The company has a strong development program dedicated to hemophilia including ongoing clinical investigations into long-acting forms of Kogenate.
Sales of the Kogenate bleeding treatment rose 16% to 205 million euros, while sales of Betaseron for multiple sclerosis increased 10% to 264 million euros.
Factor product brand names by type Plasma-free Recombinant factor Refacto, Helixate FS, Kogenate FS, VIII Advate Recombinant Factor VIII Recombinate (PRODUCTS NO LONGER MANUFACTURED: BIOCLATE, HELIXATE, KOGENATE) Plasma-derived Factor VIII Hemofil M, Monarch M, Monoclate P, Alphanate, Humate P, Koate DVI Plasma-Derived von Willebrand- Humate P (may also use Koate DVI containing Factor VIII or Alphanate which contain von Willebrand Factor but are assayed in factor VIII units) Recombinant Factor IX Benefix Plasma-Derived Factor IX Alphanine, Mononine Desmopressin DDAVP, Stimate Resources
Genentech's drug Kogenate, launched in 1993 to treat hemophilia, a disease affecting a total of 35,000 to 45,000 people in Western countries, grossed $400 million in 1999.